- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02729493
Study Evaluating the Efficacy and Safety With CAR-T for Liver Cancer (EECLC)
March 13, 2017 updated by: Sinobioway Cell Therapy Co., Ltd.
Single Arm,Two Phase,Multicenter Trial to Evaluating the Efficacy and Safety of the CAR-T for Liver Cancer
This single-arm,multicenter Phase 2 trial will treat the patients who have relapsed or refractory liver cancer with an infusion of the patient's own T cells that have been genetically modified to express a chimeric antigen receptor(CAR)that will bind to tumour cells that express the EPCAM protein on the cell surface.The study will determine if these modified T cells help the body's immune system eliminate tumour cells.The trial will also study the safety of treatment with CAR-T,how long CAR-T cells stay in the patient's body and the impact of this treatment on survival.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
This is a single-arm,multicenter Phase 2 study to evaluate the efficacy and safety of the CAR-T for Liver Cancer.The study will be conducted using a phaseⅠ /Ⅱ disign.The study will have the following sequential phases:Part A(screening leukapheresis,cell product preparation,and cytoreductive chemotherapy) and Part B(treatment and follow-up).The follow-up period for each paticipant is approximately 35 months after the final CAR-T infusion.The total duration of the study is expected to be approximately 3 years.A total of 25 patients may be enrolled over a period of 3 years.
Study Type
Interventional
Enrollment (Anticipated)
25
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Xianping Cheng, PI
- Phone Number: 13805512522
- Email: chengxianping@sina.com
Study Contact Backup
- Name: mo chen, Investigator
- Phone Number: 13605511023
- Email: chemo@sohu.com
Study Locations
-
-
Anhui
-
Hefei, Anhui, China, 230000
- Recruiting
- Anhui No.2 Province People's Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
No older than 75 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- According to UICC or liver cancer diagnosis and treatment guideline of diagnosis for hepatocellular carcinoma in patients with, the traditional treatment of invalid, advanced liver cancer, or postoperative relapse or refractory patients with hepatocellular carcinoma, and through flow cytometry or immune tissues (cell) chemistry, confirmation of tumor cells positive expression of relevant molecular targets;
- Age <=75 years old, both male and female;
- Is expected to survive more than 3 months;
- Physical condition is good: 0-2 score ECOG score;
- The lymphocyte count must > =0.4*10^9/L at the time of collection of peripheral blood;
- Vital organs (heart, kidney) function is normal, there is no major wound healing. No serious virus, bacterial infection;
- Non pregnancy and lactation;
- History of severe allergic reactions without biological products;
- Voluntary participation, good compliance,the subjects can cooperate with the experimental observation, and signed a written Informed Consent Form;
- At least one measurable lesion.
Exclusion Criteria:
- Pregnant or lactating women;
- Organ failure, such as heart: Class III and IV; liver: to Chlid grading of liver function grade C; kidney: kidney failure and uremia stage; lung: symptoms of severe respiratory failure; brain: disorder of consciousness;
- Patients with significant graft versus host disease (GVHD) after organ transplant history or allogeneic hematopoietic stem cell transplantation;
- Long term use of immunosuppressive drugs or people with severe autoimmune diseases;
- Any other chronic disease patients who have been treated with immune agents or hormone therapy;
- A serious infectious disease with severe, uncontrollable, wound healing
- Allergy to the interleukin and interferon cytokine;
- Coagulation abnormalities and severe thrombosis;
- Patients who have participated in other clinical trials or other clinical trials in the past 30 days
- The Investigator believe the patients should not participate in this experiment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single-arm
Name:The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) Dosage form:injection Dosage:100ml/time Frequency:0 days,the first day,the second day,28days,29days Duration:total five times
|
This study have only one arm that is CAR-T experimental arm.
Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-EPCAM-modified T cells can recognize and kill tumor cells in the body,follow-up 35 months.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease control rates
Time Frame: CAR - T back to lose 0 days to 180 days
|
Tumor complete remission number + partial response number + number of stable disease /Total number of cases being treated
|
CAR - T back to lose 0 days to 180 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Xianping Cheng, PI, associate chief physician
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 14, 2015
Primary Completion (Anticipated)
November 1, 2019
Study Completion (Anticipated)
November 1, 2019
Study Registration Dates
First Submitted
March 23, 2016
First Submitted That Met QC Criteria
March 31, 2016
First Posted (Estimate)
April 6, 2016
Study Record Updates
Last Update Posted (Actual)
March 15, 2017
Last Update Submitted That Met QC Criteria
March 13, 2017
Last Verified
March 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ACCO-2015-06-03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
IPD Plan Description
No plans to share data.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Neoplasms
-
Ethicon, Inc.RecruitingLiver Cancer | Cancer of the Liver | Neoplasms, LiverUnited Kingdom, United States, Netherlands, Singapore, France, Germany, China, Korea, Republic of
-
Ethicon, Inc.Terminated
-
Ewha Womans University Mokdong HospitalSeoul St. Mary's Hospital; Pusan National University Hospital; Chonnam National... and other collaboratorsUnknown
-
China Medical University HospitalActive, not recruitingLiver Transplant, Liver Cancer, ImmunosuppressantTaiwan
-
Tel-Aviv Sourasky Medical CenterCompletedPrimary Liver Tumor, Metastatic LiverIsrael
-
Fuda Cancer Hospital, GuangzhouShenzhen Hank Bioengineering InstituteCompletedLiver Tumor | Evidence of Liver TransplantationChina
-
Slawa CwajnaNova Scotia Health AuthorityWithdrawnPrimary Liver Cancer | Metastatic Liver CancerCanada
-
Chinese Academy of SciencesRecruiting
-
Dana-Farber Cancer InstituteBrigham and Women's HospitalCompleted
-
Assistance Publique - Hôpitaux de ParisFLUOPTICSUnknown
Clinical Trials on EPCAM-targeted CAR-T cells
-
Sinobioway Cell Therapy Co., Ltd.UnknownStomach NeoplasmsChina
-
Jian-Kun HuRecruitingMetastases, Neoplasm | Neoplasm Seeding | Neoplasm, StomachChina
-
Zhejiang UniversityYake Biotechnology Ltd.Not yet recruitingRefractory Multiple Myeloma | Relapse Multiple MyelomaChina
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingRefractory Multiple Myeloma | Relapse Multiple MyelomaChina
-
Zhejiang UniversityYake Biotechnology Ltd.Not yet recruitingRelapse Multiple MyelomaChina
-
Sichuan UniversityActive, not recruitingBreast Cancer Recurrent | Malignant Neoplasm of Nasopharynx TNM Staging Distant Metastasis (M) | Gastric Cancer With MetastasisChina
-
Southwest Hospital, ChinaUnknownLymphoma, Large B-Cell, DiffuseChina
-
He HuangYake Biotechnology Ltd.RecruitingRelapse/Refractory Multiple MyelomaChina
-
Zhejiang UniversityShanghai YaKe Biotechnology Ltd.Not yet recruitingAutoimmune Diseases
-
He HuangYake Biotechnology Ltd.RecruitingRelapsed and Refractory | Lymphoid Hematological MalignanciesChina